Related Experiment Video
Updated: Aug 6, 2026
04:49
Automated Counterflow Centrifugal System for Small-Scale Cell Processing
Published on: December 12, 2019
Inventory Replenishment and Transshipment for Distributed Autologous Cell Therapy Manufacturing Networks
Zhaowei Li1, Chelsea C White1, Kan Wang2
1H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
Biotechnology and Bioengineering
|July 26, 2026
Summary
A coordinated point-of-care (POC) network for autologous cell therapy (AuCT) manufacturing balances cost and patient access. This network design offers a compromise between centralized efficiency and local responsiveness for AuCT production.
Area of Science:
- Biomanufacturing and process engineering
- Healthcare systems and logistics
- Cellular therapy development
Background:
- Autologous cell therapy (AuCT) manufacturing presents a challenge in balancing production costs with timely patient access to critical treatments.
- Existing AuCT manufacturing network models include centralized facilities and independent point-of-care (POC) operations, each with inherent limitations.
- Optimizing AuCT network design is crucial for commercialization and widespread patient benefit.
Purpose of the Study:
- To compare the cost-effectiveness and patient accessibility of three distinct AuCT manufacturing network designs: centralized, coordinated POC, and independent POC.
- To evaluate the impact of network design on key operational metrics, including turnaround time and overall cost.
- To provide decision-support for optimizing AuCT manufacturing and distribution strategies.
Main Methods:
- A simulation-based analysis comparing centralized, coordinated POC, and independent POC AuCT manufacturing network models.
- Incorporation of factors such as reagent replenishment, specimen/reagent transshipment, patient deterioration, and bioreactor capacity planning.
- Utilized data from a commercial-scale AuCT network simulation with one manufacturing site, 20 POCs, and two suppliers.
Main Results:
- The coordinated POC network demonstrated total costs comparable to the centralized network.
- The coordinated POC network achieved turnaround times similar to the independent POC network.
- This hybrid approach effectively balances economic efficiency with manufacturing responsiveness.
Conclusions:
- A coordinated point-of-care (POC) manufacturing network offers a viable solution for autologous cell therapy (AuCT) production.
- This model provides a practical compromise, achieving cost efficiencies similar to centralized models while maintaining the rapid turnaround times characteristic of decentralized systems.
- Findings support the strategic implementation of coordinated distributed manufacturing for enhanced AuCT commercialization and patient access.
